May 25th 2023
Click here to answer this week's poll.
The Importance of Collaboration Between Mohs Surgeons and UrologistsMay 5th 2023
Caleb Kovell, MD and Junqian Zhang, MD demonstrated how teaming up increases the likelihood for positive patient outcomes in Mohs cases on the genitalia and perianal region.
Harnessing the Immune System to Fight Basal Cell Carcinoma: What are the Risks?January 4th 2023
In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.
Data Support the Use of First-/Second-Line Immune Checkpoint Inhibitors in HNSCCDecember 2nd 2022
Findings from a retrospective cohort study found that immune checkpoint inhibitors induced promising responses in the first- and second-line treatment of head and neck squamous cell carcinoma.